Inder Kaul, MD

Categorial Response Rates, Time Course of Response, and Symptom Domains of Response With KarXT (Xanomeline-Trospium) in the Phase 3 EMERGENT-2 Study

KarXT, a combination of xanomeline (dual M1/M4 muscarinic receptor agonist) and trospium (peripherally restricted muscarinic receptor antagonist), showed promising results in the EMERGENT...

Inder Kaul , MD;

10/26/2023

Safety and Efficacy of KarXT in Schizophrenia in the Randomized, Double-Blind, Placebo-Controlled, Phase 3 EMERGENT-3 Trial

In the EMERGENT-3 phase 3 trial, KarXT, a combination of xanomeline (M1/M4 muscarinic receptor agonist) and trospium chloride (muscarinic receptor antagonist), demonstrated significant ef...

Inder Kaul , MD;

10/26/2023